FDA approves MCS thrombosis treatment

MCS says that the system is the only device on the market that combines simultaneous venous obstruction prevention and detection during prophylactic therapy. Marketing will begin in 2012.

MCS Medical Compression Systems (DBN) Ltd. (TASE:MDCL) has obtained US Food and Drug Administration (FDA) marketing approval for its ActiveCare + Dx non-invasive device for treating deep vein thrombosis. The company will begin marketing the system in 2012.

MCS says that the system, a development of its flagship ActiveCare + SFT device, is the only device on the market that combines simultaneous venous obstruction prevention and detection during prophylactic therapy. The company added that, currently, there is a 5-6% risk of developing deep vein thrombosis in patients who receive medication and/or other therapy after orthopedic surgery, but there no treatments or technologies that can alert on prevention failure.

MCS says that the ActiveCare + Dx system will allow quicker identification of these patients and earlier treatment to begin, immediately after the presence of a blood clot is verified. Early diagnosis should greatly reduce severe complications, such as potentially lethal pulmonary embolisms.

A large clinical trial in the US found that use of ActiveCare + SFT was more effective than the deep vein thrombosis drug Lovenox on patients after hip replacement surgery. MCS says that the ActiveCare + Dx system has an advantage over medication by providing early diagnosis in patients where preventative care has failed.

MCS's share price rose 2% by midday to NIS 4.02, giving a market cap of NIS 163 million.

Published by Globes [online], Israel business news - www.globes-online.com - on May 26, 2011

© Copyright of Globes Publisher Itonut (1983) Ltd. 2011

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018